同一药理类别使用单一非劣效界值或保留比例并不合适
该研究基于PubMed、EMBASE和CENTRAL检索到的七项他汀类药物治疗高脂血症的活性对照试验(九项非劣效比较),评估在一个药理类别内统一使用单一界值或单一保留比例对非劣效性判断的影响。结果显示,单一界值对应不同对照他汀的保留比例在81%至89%之间,而单一保留比例导致九项比较中有四项(44%)的非劣效性结论与原始分析不同。结论认为,按药理类别统一使用单一界值或单一保留比例可能影响非劣效性结论。
要点
- 同一药理类别内统一使用单一非劣效界值,对应不同对照药的保留比例在81%至89%之间。
- 统一使用单一保留比例重新分析后,九项比较中有四项(44%)的非劣效性结论发生改变。
- 非劣效界值或保留比例宜按每个对照药分别设定,不宜按药理类别统一套用。
核心结论
- 按药理类别统一使用单一非劣效界值或单一保留比例,可能与按每个对照药分别设定界值或保留比例不一致,并可能影响非劣效性结论。
研究设计与样本
- 通过PubMed、EMBASE和CENTRAL检索,纳入七项他汀类药物治疗高脂血症的活性对照试验,共九项非劣效比较。
主要发现
- 使用单一界值时,不同对照他汀对应的保留比例范围为81%至89%。
- 使用单一保留比例重新分析后,九项比较中有四项(44%)的非劣效性结论与原始分析不同。
关键数值与推荐
- 单一界值下不同对照他汀对应的保留比例范围为81%至89%。
- 单一保留比例重新分析导致九项比较中四项(44%)的非劣效性结论改变。
临床怎么用
- 在非劣效试验设计中,宜针对每个对照药分别设定界值或保留比例,避免按整个药理类别统一套用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the impact on noninferiority decisions when using a single margin or single preserved fraction (PF) for all noninferiority trials within a pharmacological class. STUDY DESIGN AND SETTING: A search in PubMed, EMBASE, and CENTRAL resulted in seven active-controlled statin trials (nine noninferiority comparisons) for treating hyperlipidemia. The impact of using a single margin was assessed by calculating whether this margin corresponds to different PFs among comparator statins which will demonstrate that the threshold of demonstrating noninferiority (in terms of the PF) varies among comparator statins. The use of a single PF was assessed by reanalyzing noninferiority in the included trials with new margins (based on the single PF) for each comparator statin. RESULTS: The use of a single margin resulted in PFs that range between 81% and 89% for the different comparators (i.e., different thresholds). The use of a single PF resulted in four of nine (44%) different noninferiority conclusions compared with the original analyses. CONCLUSION: The threshold of demonstrating noninferiority with a single margin or single PF of the effect per pharmacological class may not be consistent with using a margin/PF for each comparator separately and may impact the conclusions of noninferiority.
引用
- Althunian TA, de Boer A, Groenwold RHH, et al. Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate. J Clin Epidemiol. 2018. PMID: 30009941. doi:10.1016/j.jclinepi.2018.07.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。